Related Experiment Video
Updated: Jul 30, 2026
09:57
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Fast dissolving drug-drug eutectics with improved compressibility and synergistic effects
Rajesh Thipparaboina1, Dinesh Thumuri2, Rahul Chavan1
1Solid State Pharmaceutical Research Group (SSPRG), , Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, India.
Summary
Novel drug-drug eutectics of etodolac with paracetamol (EP) and etodolac with propranolol hydrochloride (EPHC) were synthesized, showing enhanced dissolution and material properties. These combinations offer improved therapeutic effects for osteoarthritis and cancer chemotherapy.
Area of Science:
- Pharmaceutical Sciences
- Supramolecular Chemistry
- Drug Delivery Systems
Background:
- Combinational therapy offers advantages such as enhanced efficacy and patient compliance.
- Drug-drug multicomponent adducts enable supramolecular drug combinations.
- Etodolac, paracetamol, and propranolol hydrochloride are common therapeutic agents.
Purpose of the Study:
- To design and synthesize novel drug-drug eutectics of etodolac with paracetamol (EP) and etodolac with propranolol hydrochloride (EPHC).
- To evaluate the dissolution and material properties of these novel eutectic mixtures.
- To assess the therapeutic potential of EP and EPHC in relevant cell culture models.
Main Methods:
- Synthesis of etodolac-paracetamol (EP) and etodolac-propranolol hydrochloride (EPHC) eutectics.
- Dissolution efficiency and hardness testing of eutectic mixtures compared to pure drugs.
- Cell culture studies including Western blotting for inflammatory mediators (TNF-α, COX-2, IL-6) and cytotoxicity assays.
Main Results:
- Successfully synthesized EP and EPHC eutectics with significantly improved dissolution rates (6-9 fold enhancement in % dissolution efficiency at 1 min).
- Eutectic mixtures exhibited enhanced hardness (EP: ~5 fold, EPHC: ~3 fold improvement at 10 MPa).
- EP demonstrated reduced inflammatory mediators; EPHC showed enhanced cytotoxic effects with synergistic and favorable dose reduction indices.
Conclusions:
- EP and EPHC represent promising multi-component systems with fast-dissolving capabilities and improved material properties.
- These eutectic combinations show potential for effective treatment of osteoarthritis (EP) and cancer chemotherapy (EPHC).
- The study highlights the utility of supramolecular adducts for developing advanced combination therapies.
Related Concept Videos
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...